|
|
Blood, 15 January 2007, Vol. 109, No. 2, pp. 457-464.
Prepublished online as a Blood First Edition Paper on September 21, 2006; DOI 10.1182/blood-2006-07-035352.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
Ashutosh D. Wechalekar1,,
Hugh J. B. Goodman1,
Helen J. Lachmann1,
Mark Offer1,
Philip N. Hawkins1, and
Julian D. Gillmore1
1 National Amyloidosis Centre, Centre for Amyloidosis & Acute Phase Proteins, Department of Medicine (Hampstead Campus), Royal Free and University College Medical School, London, United Kingdom
High-dose melphalan with stem-cell transplantation is believed to be the most effective treatment for systemic light-chain (AL) amyloidosis, but many patients are ineligible because of the extent of their disease, and treatment-related mortality (TRM) remains substantial. We report the use of a risk-adapted oral regimen of cyclophosphamide, thalidomide, and dexamethasone (CTD) or attenuated CTD (CTDa) in 75 patients with advanced AL amyloidosis, including 44 patients with clonal relapse after prior therapy. Fifty-one (68%) patients received CTD and 24 (32%) received CTDa. A hematologic response occurred in 48 (74%) of 65 evaluable patients, including complete responses in 14 (21%) and partial responses in 34 (53%) cases. Median estimated overall survival (OS) from commencement of treatment was 41 months, and from diagnosis median was not reached with a median follow-up of 22 months. Three-year estimated OS was 100% and 82% among complete and partial hematologic responders, respectively. Toxicity necessitating cessation of therapy occurred in 8% and was at least grade 2 in 52% of patients. TRM was 4%. The clonal response rates to CTD reported here are higher than any previously reported nontransplantation regimen in AL amyloidosis, and risk adaptation allows its use in poorer risk patients. CTD merits prospective randomized study.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
A triple on AL amyloidosis, waiting for a home run
- Geraldine P. Schechter
Blood 2007 109: 391-392.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
A. D. Wechalekar, H. J. Lachmann, M. Offer, P. N. Hawkins, and J. D. Gillmore
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease
Haematologica,
February 1, 2008;
93(2):
295 - 298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kumar, A. Dispenzieri, M. A. Gertz, J. Mehta, H. J. Lachmann, A. D. Wechalekar, J. D. Gillmore, H. M. Lokhorst, B. P.C. Hazenberg, A. Croockewit, et al.
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
N. Engl. J. Med.,
January 3, 2008;
358(1):
91 - 92.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mehta
Amyloidosis: graviores morbos, asperis remedii
Blood,
November 15, 2007;
110(10):
3490 - 3491.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Kastritis, A. Anagnostopoulos, M. Roussou, S. Toumanidis, C. Pamboukas, M. Migkou, A. Tassidou, I. Xilouri, S. Delibasi, E. Psimenou, et al.
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone
Haematologica,
October 1, 2007;
92(10):
1351 - 1358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Gertz, M. Q. Lacy, A. Dispenzieri, S. R. Hayman, S. K. Kumar, N. Leung, and D. A. Gastineau
Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response
Haematologica,
October 1, 2007;
92(10):
1415 - 1418.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Merlini
Refining therapy for AL amyloidosis
Blood,
December 1, 2006;
108(12):
3632 - 3633.
[Full Text]
[PDF]
|
|
|
| |
